参考文献/References:
[1] Schneider JS,Sendek S,Daskalakis C,et al.GM1 ganglioside in Parkinson's disease: results of a five year open study[J].Neurol Sci,2010,292(1/2):45-51.
[2] Yuki N.Human gangliosides and bacterial lipo-oligosaccharides in the development of autoimmune neuropathies[J].Methods Mol Biol,2010, 600(600):51-65.
[3] Lucki NC,Sewer MB. Nuclear sphingolipid metabolism[J]. Ann Rev Physiol,2012,74(1):131-151.
[4] Schnaar RL, Gerardy-Schahn R, Hildebrandt H. Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration[J]. physiological reviews, 2014, 94(2):461-518.
[5] Allende ML,Proia RL.Simplifying complexity: Genetically resculpting glycosphingolipid synthesis pathways in mice to reveal function[J]. Glycoconj J,2014,31(9):613-622.
[6] Wang J, Cheng A, Wakade C, et al. Ganglioside GD3 is required for neurogenesis and long-term maintenance of neural stem cells in the postnatal mouse brain[J]. The Journal of Neuroscience:the Official Journal of the Society for Neuroscience, 2014, 34(41):13790-13800.
[7] Bisel B,Pavone FS,Calamai M.GM1 and GM2 gangliosides: Recent developments[J]. Biomol Concepts,2014,5(1):87-93.
[8] Schneider JS, Gollomp SM, Sendek S, et al. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients[J]. Journal of the Neurological Sciences, 2013, 324(1/2):140-148.
[9] Yu RK, Usuki S, Ariga T. Ganglioside molecular mimicry and its pathological roles in Guillain-Barre syndrome and related diseases[J]. Infection and Immunity, 2006, 74(12):6517-6527.
[10] Schwerer B, Pichler S, Bernheimer H, et al. Chronic progressive motor polyneuropathy after ganglioside treatment[J]. Journal of Neurology, Neurosurgery, and Psychiatry, 1994, 57(2):238.
[11] Granieri E, Casetta I, Govoni V, et al. Ganglioside therapy and Guillain-Barrésyndrome A historical cohort study in Ferrara, Italy, fails to demonstrate an association[J]. Neuroepidemiology, 1991, 10(4):161-169.
[12] Illa I, Ortiz N, Gallard E, et al. Acute axonal Guillain-Barre syndrome with IgG antibodies against motor axons following parenteral gangliosides[J]. Annals of Neurology, 1995, 38(2):218-224.
[13] Di'ez-tehedor E. Gutie'rrez-rivas E,Gil-Peralta A.gangliosides and Guillain-Barre syndrome: the Spanish data[J]. Neuroepidemiology, 1993, 12(5):251-256.
[14] Yuki N, Odaka M. Ganglioside mimicry as a cause of Guillain-Barrésyndrome[J]. Current Opinion in Neurology, 2005, 18(5):557-561.
[15] Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside[J]. Annals of Neurology, 2001, 49(6):712-720.
[16] Islam Z, Gilbert M, Mohammad Q D, et al. Guillain-Barré syndrom-erelated campylobacter jejuni in Bangladesh: ganglioside mimicry and cross-reactive antibodies[J]. PLOS One, 2012, 7(8):e43976.
[17] Wu XJ, Wu W, Wang ZZ, et al. More severe manifestations and poorer short-term prognosis of ganglioside-associated Guillain-Barré syndrome in Northeast China[J]. PLOS One, 2014, 9(8):e104074.
[18] Moriguchi K, Miyamoto K, Takada Kazuo, et al. Four cases of anti-ganglioside antibody-positive neuralgic amyotrophy with good response to intravenous immunoglobulin infusion therapy[J]. Journal of Neuroimmunology, 2011, 238(1/2):107-109.